100707-39-9

Basic information

• Product Name: 5-Bromo-2-methyl-4-pyrimidinecarboxylic acid
• Synonyms: 5-Bromo-2-methylpyrimidine-4-carboxylic acid;4-PyriMidinecarboxylic acid, 5-broMo-2-Methyl-;5-Bromo-2-methylpyrimidin-4-carboxylic acid
• CAS NO: 100707-39-9
• Molecular Formula: C₆H₅BrN₂O₂
• Molecular Weight: 217.02
• Product Categories: pharmacetical;Heterocycle-Pyrimidine series
• Mol File: 100707-39-9.mol
• Article Data: 4

Chemical Properties

• Melting Point: 172-173 °C (decomp)(Solv: methanol (67-56-1))
• Boiling Point: 335.169 °C at 760 mmHg
• Flash Point: 156.505 °C
• Appearance: /
• Density: 1.795 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.61
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 1.53±0.10(Predicted)
• CAS DataBase Reference: 5-Bromo-2-methyl-4-pyrimidinecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-2-methyl-4-pyrimidinecarboxylic acid(100707-39-9)
• EPA Substance Registry System: 5-Bromo-2-methyl-4-pyrimidinecarboxylic acid(100707-39-9)

Safety Data

• Hazardous Substances Data: 100707-39-9(Hazardous Substances Data)

Usage

General Description

5-Bromo-2-methyl-4-pyrimidinecarboxylic acid is a chemical compound with the molecular formula C6H5BrN2O2. It belongs to the chemical class of Pyrimidines and Puritymidinediones, which are compounds containing a pyrimidine ring, a six-member aromatic heterocycle made up of two nitrogen atoms and four carbon atoms. It typically appears as an off-white or beige crystalline powder at room temperature. It is used in various scientific and industrial applications, mainly in the field of organic synthesis and pharmaceuticals.

InChI:InChI=1/C6H5BrN2O2/c1-3-8-2-4(7)5(9-3)6(10)11/h2H,1H3,(H,10,11)

Upstream product

• 488-11-9 mucobromic acid 
• 124-42-5 acetamidine hydrochloride 
• 90994-06-2 (2E)-2,3-dibromo-4-oxobut-2-enoic acid 
• 766-38-1 mucobromic acid 

Downstream Products

• 99989-21-6 5-anilino-2-methyl-pyrimidine-4-carboxylic acid 
• 7496-32-4 6-methyl-1H-pyrimido[5,4-d]pyrimidine-2,4-dione 
• 7752-78-5 5-bromo-2-methylpyrimidine 
• 113949-10-3 5-methoxy-2-methylpyrimidine-4-carboxylic acid 
• 1193116-74-3 5-bromo-2-(bromomethyl)pyrimidine 
• 1235451-38-3 tert-butyl (5-bromopyrimidin-2-yl)methylcarbamate 
• 1240783-02-1 (5-bromopyrimidin-2-yl)methylamine 
• 311335-74-7 5-Bromo-2-methyl-pyrimidine-4-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide 
• 311334-73-3 2-Methyl-5-phenyl-pyrimidine-4-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methyl-amide 
• 311335-73-6 5-Bromo-2-methyl-pyrimidine-4-carboxylic acid 3,5-bis-trifluoromethyl-benzylamide 

Relevant articles and documents

-

-

NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES

It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B1 is a radical selected from the group consisting of formula (A"), formula (B"), formula (C"), and formula (D"):

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.